Refillable-nanofluidic implants for HIV PrEP · 1 Refillable-nanofluidic implants for HIV PrEP...

14
1 Refillable-nanofluidic implants for HIV PrEP September 5th, 2018 Alessandro Grattoni, Ph.D. Chairman and Professor, Department of Nanomedicine, Houston Methodist Research Institute, Houston George and Angelina Kostas

Transcript of Refillable-nanofluidic implants for HIV PrEP · 1 Refillable-nanofluidic implants for HIV PrEP...

1

Refillable-nanofluidic implants

for HIV PrEPSeptember 5th, 2018

Alessandro Grattoni, Ph.D.Chairman and Professor, Department of Nanomedicine,

Houston Methodist Research Institute, Houston

George and Angelina Kostas

2

Time

Pla

sm

a c

on

ce

ntr

ati

on

Constant admin.

THE NEED FOR ALTERNATIVE DRUG DELIVERY STRATEGIES

Conventional admin. Controlled kinetics

✓ Repetitive admin.

✓ Large drug doses

✓ Adverse side effects

✓ Poor compliance

Time Time

Toxicity

Therapeutic range

Reduced activity

Toxicity

Therapeutic

range

Reduced activity

Toxicity

Reduced activity

Therapeutic

✓ Sustained release

✓ Minimization of drug dose

✓ Reduced side effects

✓ Assure compliance

✓ Bio-responsive

✓ Ad hoc delivery

3

SUSTAINED DRUG DELIVERY SYSTEMS

Osmotic pumps Wearable external pumps

Reservoir-based

polymeric Implants

MicroCHIP devices

Long-acting depotsBiodegradable

polymeric rods

4

NANOFLUIDICS

Electrokinetic transportConcentration-driven transport

5.5 nm

No pumps

No valves

5

NANOCHANNEL MEMBRANE

6Ferrati et al.

JCR, 2013

NANOCHANNEL SELECTION

7

NANOCHANNEL IMPLANTS

Ferrati et al. J. Controlled Release, 2013

Ferrati et al. Advanced Healthcare Materials, 2014

Hood R.L. et al. J. Biomedical Nanotechnology, 2016

8

HIV STATISTICS

9

HIV PrEP FACTS

TRUVADA (Gilead) = TDF + FTC

TDF = Tenofovir Disoproxil Fumarate (nucleoside reverse transcriptase inhibitor)

FTC = Emtricitabine (NRTI)

TAF = Tenofovir Alafenamide Fumarate (nucleotide reverse transcriptase inhibitor)

Grant RM et al. New Engl Jour Med, 2010.

10

H

NANOFLUIDIC IMPLANT

FOR HIV PREVENTION

11

NANOFLUIDIC IMPLANT FOR

HIV PREVENTION TAF+FTC

Chua et al. JCR,

Accepted, 2018

12

The TEAM

• Jagan Sastry, Ph.D. MD Anderson

• Roberto Arduino, M.D. UTHSC Medical School

• Mark Marzinke, Ph.D. Johns Hopkins University

• Peter Anderson, Ph.D. UC Denver

• Jason Kimata, Ph.D. Baylor College of Medicine

• Pramod Nehete, Ph.D. MD Anderson, Bastrop

• Kathryn Shelton, Ph.D. MD Anderson, Bastrop

13

ACKNOWLEDGEMENTS

A. Grattoni’s Laboratory• Carly Filgueira, Ph.D. Assistant Professor

• Antons Sizovs, Ph.D. Research Associate

• Corrine Chua Ying Xuan, Ph.D. Research Associate

• Giacomo Bruno, Ph.D Postdoctoral Fellow

• Fernanda Pons, M.D., Ph.D. student

• Jeremy Ho, M.D. student

• Marco Farina, Ph.D. student

• Giovanni Scorrano, Ph.D. student

• Jessica Rhudy, M.S.

• Veronica Vighetto, M.S. student

• Nicola Di Marzio, M.S. student

• Antonia Silvestri, Ph.D. student

• Nicola Di Trani, M.S. student

• Matteo Hirsch, M.S. student

• Maria Luisa Lotito, M.S. student

• Antonia Susnjar, B.S. Research Assistant

• Lisa Rose, B.S. Academic Coordinator

George and Angelina Kostas

Department of Nanomedicine• Mauro Ferrari, Ph.D.

• Haifa Shen, Ph.D.

• Milos Kojic, Ph.D.

• Arturas Ziemys, Ph.D.

Collaborators• Alberto Pimpinelli, Ph.D.

• Jagan Sastry, Ph.D.

• Roberto Arduino, M.D.

• Mark Marzinke, Ph.D.

• Peter Anderson, Ph.D.

• Osama Gaber, M.D.

• Ghanashyam Acharya, Ph.D.

• Brian Butler, M.D.

• Sankar Mitra, Ph.D.

• Pandita Tej, Ph.D.

• Sam Cadena, Ph.D.

• Xian C. Li, M.D., Ph.D.

14

FOLLOW US

Laboratory Profile:https://bit.ly/grattoni

Follow us: @grattonilab